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Figure S1. Shp-2 is deleted in T cells and CD4cre Ptpn11fl/fl mice show normal T cell selection and peripheral homeostasis . 
Related to Figure 1. A) Total T cells were enriched from spleens of CD4cre Ptpn11wt/wt, CD4cre Ptpn11fl/fl and Ptpn11fl/fl mice. The 
remaining fraction is indicated as T cell-negative. Expression of Shp-2 or Shp-1 was tested by immunoblot in cell lysates from the 
indicated subsets, actin used as loading control. T cell purity was over 90%, whereas T cell contamination in T cell-depleted 
spenocytes less than 5%. B) CD8+ T cells were enriched from spleens of P14 transgenic CD4cre Ptpn11fl/fl and Ptpn11fl/fl mice, with a 
purity of over 97%. Cell were activated with plastic-bound α-CD3 and α-CD28 (1μg/ml each, in the presence of 10 ng/ml IL-2) for 48 
hours and cultured for additional 48 hours (in the presence of 20 ng/ml IL-2). Cells were then collected and expression of Shp-2 or 
Shp-1 was tested by immunoblot (left panel) and abundance of Ptpn11 mRNA determined by quantitative RT-PCR (relative to Polr2a; 
right panel). Quantitative RT-PCR data represent mean ± SD of n=3 technical replicates and are representative of at least two 
independent experiments. C-F) Analysis of thymi from P14-transgenic CD4cre Ptpn11fl/fl and Ptpn11fl/fl mice. C and D) Cellularity (C) 
and percentages of DN, DP, and SP thymocytes among lineage-negative lymphocytes (D) are depicted. E and F) A representative 
histogram illustrates the levels of CD5, CD24, and CD69 (E) and of Vα2 and TCRβ (F) on DP and CD8 SP. G) Inguinal lymph nodes 
(LNs) cellularity and percentages of CD4+ (CD4+ CD3+) and CD8+ (CD8+ CD3+) T cells (gated on lymphocytes) in CD4cre 
Ptpn11wt/wt, CD4cre Ptpn11fl/fl, and Ptpn11fl/fl mice are illustrated. H and I) Percentages of naïve (CD44low-int CD62Lhigh), “CM-like” 
(CD44high CD62Lhigh), and “EM-like” (CD44high CD62Llow) CD4+ and CD8+ T lymphocytes in the iLNs of the afore-mentioned mice (H) 
and a representative flow cytometry plot of CD62L and CD44 expression (I) are depicted. Results represent mean ± SEM of n=4 mice/
group (C and D) and of n=3-5 mice/group (G and H) and are representative of two (C-F) or at least two (G-I) independent 
experiments. Only statistically significant differences are shown (B-D, G and H); Student’s t-test; ***p ≤ 0.001
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Figure S2. Characterization of T cells in CD4cre Ptpn11fl/fl mice during chronic LCMV. Related to Figure 2
A) Graph illustrates percentages of CD4+ T cells at day 8 and 20 p.i. in blood of CD4cre Ptpn11wt/wt, CD4cre Ptpn11fl/fl
and Ptpn11fl/fl mice. B) Graphs depict percentages and numbers of CD4+ T cells, percentages of CD62L low CD44
high (CD62Llo CD44hi), and of CD62L low PD-1 high (CD62Llo PD-1hi) CD4+ T cells at day 34 p.i. in the spleen of
the afore-mentioned mice. C) Representative flow cytometry plots of CD62L/CD44 or CD62L/PD-1 expression on
CD8+ T cells at day 34 p.i. in the spleen. D) Graph shows spleen cellularity of CD4cre Ptpn11wt/wt, CD4cre Ptpn11fl/fl
and Ptpn11fl/fl mice at day 34 p.i.. E) Graphs illustrate percentages of CD8+, CD44high CD62Llow effector, PD1+, and
gp33-specific (gp33+) T cells among lymphocytes in the spleen of CD4cre Ptpn11wt/wt, CD4cre Ptpn11fl/fl, and CD4cre
Ptpn11wt/fl mice at day 34 p.i.. A, B, D, and E) Results are a pool of two independent experiments, and mean ± SEM
of n=6-15 (A), n=6-12 (B and D), n=7-8 (E) mice/group. Only differences statistically significant in comparison to
both controls are shown; **p ≤ 0.01, ***p ≤ 0.001; Student’s t-test
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Figure S3. Ptnp11- and Pdcd1- deficient T cells show profound differences in expansion upon chronic LCMV. Related to 
Figure 3. Wild type recipient mice (CD45.2) were co-transferred with a mix of 400 control (Ptpn11fl/fl, CD45.1) and 400 
Ptpn11-deficient (KO; CD4cre Ptpn11fl/fl, CD45.1/2) P14 CD8+ T cells and infected with LCMV clone 13. In parallel, wild 
type mice (CD45.1/2) were co-transferred with a mix of 400 control (CD45.1) and 400 Pdcd1-deficient (KO; CD45.2) P14 
CD8+ T cells and infected with LCMV clone 13. A) Percentages of KO and control P14 T cells in the initial mix and in the 
spleen at day 11 p.i. are shown as a representative flow cytometry plot (gated on Va2+ CD8+ T cells). B) The graph depicts the 
ratio of Ptpn11- or Pdcd1- deficient over control (normalized to the initial mix) at day 11 in individual mice (n=5 mice/group); 
Only statistically significant differences are shown; ***p ≤ 0.001; Student’s t-test.
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Figure S4. Functional characterization of Ptnp11-deficient T cells during chronic LCMV. Related to Figure 4
A-D) Wild type recipient mice were co-transferred with a 1:1 mix of congenically-marked control (CD4cre Ptpn11wt/wt) and
Ptpn11-deficient P14 CD8+ T cells and infected with LCMV clone 13 or Armstrong, as a control. A-D) Splenocytes isolated at
day 30 from infected mice were restimulated with gp-33 peptide pulsing and stained for CD107a (A and B), IFN-γ and TNF-α
(C and D). Graphs (A, C) illustrate frequencies of CD107a+ (A), IFN-γ+, and TNFα+ among IFN-γ+ (C) Ptpn11-deficient and
control P14 T cells, and representative flow cytometry pictures are shown (B, D). Results depict mean ± SEM of n=3-4
(Armstrong) and n=5-6 (clone 13) (A and C). Results confirm data shown in Figure 4B and C and were performed once with
gp-33 restimulation (A and B) or are representative of at least two independent experiments (C and D). E and F) Viral titers at
the indicated times in serum (E) and 34 days after infection with LCMV clone 13 in the kidney (F) from CD4cre Ptpn11wt/wt,
CD4cre Ptpn11fl/fl and Ptpn11fl/fl mice. Results illustrate mean ± SEM of n=4-9 mice/group (E) and n=6-12 mice/group (F) and
are a pool of two independent experiments. Only statistically significant differences are shown; *p ≤ 0.05, Student’s t-test.
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Figure S5. Control of MC38 engraftment in the absence of PD-1 signaling, helper T cells, and Shp2. Related to Figure 5. 
A) Wild type and Pdcd1-deficient mice were subcutaneously inoculated with MC38 cells. Tumor growth in individual mice is 
shown at day 5 (on the left) and over time (on the right); the number of mice completely controlling tumor growth in each group is 
indicated within the graphs. B) Mice of the indicated genotypes were subcutaneously inoculated with MC38 cells. Graph depicts 
tumor volume 5-6 days after (depending on the experiment), when mice were randomized as indicated and treatment with α-PD1 
antibody or isotype control was started. C) CD4cre Ptpn11wt/wt and CD4cre Ptpn11fl/fl mice were depleted of CD4+ T cells by 
weekly i.p. injections of α-CD4-depleting antibody (GK1.5, BioXcell, 200 μg/mouse), or PBS as control, starting two days prior 
to MC38 engraftment. Tumor growth in individual mice is shown (on the left); the number of mice completely controlling tumor 
growth in each group is indicated next to the graphs. Survival curves and statistical comparisons are shown (on the right). D-F) 
CD4cre Ptpn11fl/fl and Ptpn11fl/fl mice were inoculated with MC38 cells. D) Graphs show tumor volume 5 days after inoculation 
(on the left), when mice were divided as indicated and treatment with α-PD-1 antibody or isotype control was started, and 12 days 
(on the right) after inoculation and three injections of α-PD1 antibody or isotype control. E) Graph depicts the percentage of 
infiltrating T helper cells (gated as CD8- CD3+, which largely correspond to CD4+ T lymphocytes) in isotype and α-PD-1 
antibody-treated mice among hematopoietic cells. F) Percentage of PD-1+, Lag-3+, and 2B4+ among CD8+ T cells infiltrating 
tumors from isotype-treated CD4cre Ptpn11fl/fl and Ptpn11fl/fl mice. Results depict n=7-11 mice/group (C, right panel), and mean ± 
SEM of n=7-8 mice/group (A, left panel), of n=9-11 mice/group (B), of n=3-9 mice/group (D-F). Data are a pool of two 
independent experiments (A-D and F) and a representative graph of two independent experiments (E). Only statistically 
significant differences are indicated; Student’s t-test. C) For survival, comparisons are by log-rank (Mantel-Cox) test.
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Supplemental Experimental procedures
Flow cytometry: surface and intracellular staining
For flow cytometry analysis, cells were pre-incubated with α-CD16/32 (2.4G2) to block Fc receptors and then surface 
stained using antibodies against CD3e (145-2C11), CD4 (GK1.5, RM4-5), CD5 (53-7.3), CD8a (53-6.7), CD24 ( M1/69), 
CD44 (IM7), CD45.1 (A20), CD45.2 (104), CD62L (MEL-14), CD69 (H1.2F3), PD-1 (J43, 29F.1A12), Lag3 
(ebioC9B7W), 2B4 (ebio244F4), Tigit (1G9), and CD107 (ebio1D4B). Antibodies were purchased from eBioscience or 
Biolegend. The H-2Db–gp33 H-2Db–gp276 tetramer was from TCMetrix. Stainings were performed with appropriate 
combinations of fluorophores; streptavidin conjugated fluorophores were from eBioscience. To gate on thymocytes, the 
lineage mix used contained anti-B220 (RA3-6B2), -NK1.1 (PK136), -F4/80 (BM8), -CD11c (N418), and -TCRγδ 
(eBioGL3). Proliferation was assessed by the detection of Ki67 ex vivo. Intracellular staining for Ki67 (anti-Ki67, clone 
SolA15) was performed post surface staining using the Transcription factor fixation/permeabilization buffer from 
eBioscience following the recommended protocol. Transcription factors were detected using the transcription factor staining 
kit from eBioscience and staining with mAbs for Eomes (Dan11mag), T-bet (eBio4B10) (both from eBioscience) or Tcf1 
(C63D8, Cell Signaling) followed by anti-rabbit IgG APC (SouthernBiotech). Data were acquired with a Becton Dickinson 
flow cytometer and analysed using FlowJo software (Tree Star).
Cytokine production/degranulation capacity assay
Total splenocytes from LCMV-infected mice were cultured for two hours with anti-CD3 or anti-CD3/CD28 (coated 
overnight with 2 μg/ml anti-CD3e (145-2C11-ebio, eBioscience) only, or 2 μg/ml anti-CD3e and 2 μg/ml of anti-CD28 
(37.51, eBioscience)). Then, Brefeldin A (10 μg/ml) was added and cells were cultured for two additional hours. For gp33 
peptide restimulation, total splenocytes were incubated 4 hours with 1 μM LCMV gp (33-41) peptide (EMC 
microcollections), in the presence of Brefeldin A (10 µg/ml) for the last 3 hours. Cells were first surface stained, then fixed 
with 4% paraformadeyde and permeabilized with 0.5% saponin (Sigma) in PBS for 15 minutes. After permeabilization, cells 
were then stained for the indicated cytokines (TNF-α clone MP6-XT22, IFN-γ clone XMG1.2, IL-2 clone JE6-5H4). 
Degranulation capacity was determined incubating the cells during the stimulation with anti-CD107 (ebio1D4B). 
Immunoblot analysis
Total T cells and CD8+ T cells were enriched using α-CD4 and α-CD8a magnetic beads or α-CD8a magnetic beads (Miltenyi 
Biotec) only, respectively. T cell purity was over 90%, whereas T cell contamination in T cell-depleted spenocytes less than 
5%. Rabbit polyclonal anti-mouse Shp-2 (D50F2) and Shp-1 (C14H6) were obtained from Cell Signaling. α-β-actin was 
from Abcam.
Quantitative PCR
RNA extraction, retrotranscription to cDNA, and expression analysis were done as previously described (Ludigs et al., 
2015). The Following primers were used:
Ptpn11 fwd: 5’- AGACTTCGTTCTCTCCGTGC-3’
Ptpn11 rev 5’- CTGTCAGAGAGTCAAAGCGC-3’ 
polr2a fwd 5’- CCGGATGAATTGAAGCGGATGT-3’
polr2a rev: 5’-CCTGCCGTGGATCCATTAGTCC-3’
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